SRR1797303
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 55
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- COAGULATION+0.390
- ANGIOGENESIS+0.370
- COMPLEMENT+0.350
- UV_RESPONSE_DN+0.330
- TNFA_SIGNALING_VIA_NFKB+0.310
- KRAS_SIGNALING_UP+0.300
- ANDROGEN_RESPONSE+0.260
- PROTEIN_SECRETION+0.260
Top 10 suppressed
- DNA_REPAIR-0.330
- E2F_TARGETS-0.220
- OXIDATIVE_PHOSPHORYLATION-0.220
- P53_PATHWAY-0.180
- GLYCOLYSIS-0.140
- ADIPOGENESIS-0.110
- NOTCH_SIGNALING-0.080
- WNT_BETA_CATENIN_SIGNALING-0.080
- FATTY_ACID_METABOLISM-0.060
- PEROXISOME-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797300 | — | cohortMD2 | 0.905 |
| 2 | SRR1797276 | — | cohortMD2 | 0.887 |
| 3 | MBCProject_3122_T1_RNA | — | A | 0.853 |
| 4 | ERR2598110 | fetal | fetal | 0.834 |
| 5 | aad90266-d469-4986-b260-d0df4c2f48e7 | — | — | 0.832 |
| 6 | MNG639 | — | — | 0.826 |
| 7 | ffe7358d-31b2-4d92-93eb-0a88abaf2dca | — | — | 0.813 |
| 8 | SRR23303737 | — | — | 0.812 |
| 9 | SRR35579817 | — | A | 0.811 |
| 10 | MNG918 | — | — | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.520 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |